The Serum Institute of India (SII) has stated that the company is going to produce 30 to 40 lakh doses of the experimental Kovid-19 vaccine developed by Oxford University and AstraZeneca by December this year. Let us know that SII is the largest vaccine manufacturer in the world. It has partnered with the biopharmaceutical company AstraZeneca to manufacture the experimental Kovid-19 vaccine developed by the University of Oxford.
SII Chief Executive Officer Adar Poonawalla said that ‘Kovishield’ is the first Kovid-19 vaccine, which is expected to be launched if trials are successful in both the UK and India. Scientists on Monday announced after the first phase of its human testing that this potential corona virus vaccine appeared safe so far and was effective in producing strong immunity within the body.
According to the results of the trial published in The Lancet Medical Journal on Monday, more than 1,000 healthy adults between the ages of 18 and 55 were given vaccine doses in five hospitals in the UK in April and May. The vaccine did not show any serious side effects and a good response was found in people receiving two doses. AstraZeneca has tied up with Pune-based Serum Institute for the manufacture and supply of vaccines in India along with more than 60 other countries with a combined population of 3 billion.
Vaccine supplements
Poonwala has said that 30 to 40 lakh doses of the experimental Kovid-19 vaccine developed by Oxford University and AstraZeneca are being produced by December this year. We will prepare in a big way in mid-August. By the end of this year, we are able to produce 3 to 4 million doses.
If planned, the phase 3 trial will take two months after the dose is given to the patients and the vaccine will get final approval by November. He said that in such a situation it may come in the first quarter of 2021 also.
He stated that it is likely that only two or more doses of the Kovid-19 vaccine would be required, as is the case for measles and other diseases. “We (Oxford-AstraZeneca) have got a lot of results and we are very happy. We hope it works,” he said.
Covshield price
Poonawala said that he expects the vaccines to reach a large number of people in India by the first quarter of 2021. We are going to give it at a very cheap price … We are planning to keep it at around 1000 rupees or less … I don’t think any citizen of India or any other country will have to pay for it. . Because it is being purchased by the government and will be distributed for free.
He said- It will be given at a very cheap price. In fact, after the epidemic is over we want to make more profit, we can consider a more commercial price which may be available in the market.
Trial
Poonawalla said that after the necessary inconvenience, the trial of the Kovid 19 vaccine will start at the end of August on up to five thousand volunteers and if all goes well, the company will launch Kovishield around June next year.
